CliffBio
biologic

Bivigam

Immune Globulin Intravenous (Human)

Loss of exclusivityDecember 2024projected — 12-year biologic exclusivity estimate
CompanyADMA Biologics →See this company's full patent-cliff portfolio

Drug detail

Brand nameBivigam
Active ingredientImmune Globulin Intravenous (Human)
Strength10GM/100ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2012
Marketing statusRx

More from ADMA Biologics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Bivigam patent cliff — loss of exclusivity December 2024 | CliffBio